Goodipine T Tablet is a combination antihypertensive medication containing Cilnidipine 10 mg and Telmisartan 40 mg, indicated for the management of essential hypertension. Cilnidipine, a calcium channel blocker of the dihydropyridine class, exerts its antihypertensive effect by inhibiting L-type and N-type calcium channels, leading to vasodilation of peripheral arteries and reduction in sympathetic nerve activity. Telmisartan, an angiotensin II receptor blocker (ARB), selectively antagonizes the AT1 receptor, thereby preventing vasoconstriction and aldosterone secretion induced by angiotensin II. The synergistic action of these agents effectively lowers blood pressure, reducing the risk of cardiovascular events such as stroke and myocardial infarction. Goodipine T Tablet is particularly beneficial for patients requiring dual mechanism therapy to achieve optimal blood pressure control. It is generally well tolerated, with common adverse effects including dizziness, headache, and mild peripheral edema. Use of this combination should be carefully monitored in patients with renal impairment, hepatic dysfunction, or electrolyte imbalances. Regular blood pressure monitoring and periodic assessment of renal function and serum electrolytes are recommended during therapy. Goodipine T Tablet should be used under medical supervision, adhering to prescribed dosage to ensure efficacy and safety.